Infinity Pharmaceuticals, Inc. (INFIQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerInfinity Pharmaceuticals, Inc. (INFIQ) trades at $0.0001. Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. The company is currently navigating a Chapter 11 liquidation process while developing its lead product candidate, eganelisib. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for INFIQ: INFIQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Infinity Pharmaceuticals, Inc. (INFIQ) Healthcare & Pipeline Overview
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to creating novel cancer treatments, particularly through its lead candidate eganelisib, while strategically collaborating with industry partners to enhance its research and development capabilities.
What Is the Investment Thesis for INFIQ?
Infinity Pharmaceuticals, Inc. is currently positioned in a challenging financial landscape following its Chapter 11 liquidation approval. The company's lead product candidate, eganelisib, remains in clinical development, with potential catalysts tied to trial outcomes in the oncology space. The strategic alliances with firms like Verastem and Bristol Myers Squibb provide a framework for future collaborations, which could enhance product development and commercialization efforts. However, the absence of revenue generation and the high beta of 8.79 indicate substantial volatility and risk. Investors should closely monitor trial results and any developments regarding potential partnerships or licensing agreements that could provide liquidity and operational stability in the coming years.
Based on FMP financials and quantitative analysis
INFIQ Key Highlights
Market Cap: $0.00B, indicating a significant downturn in financial health.
- Beta: 8.79, reflecting high volatility compared to the market.
- Employees: 30, showcasing a lean operational structure amidst financial restructuring.
- No dividend yield, aligning with the company's focus on growth and development rather than returning capital to shareholders.
- Current status involves Chapter 11 liquidation, impacting future operational capabilities.
Who Are INFIQ's Competitors?
INFIQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $503.50 | -0.24% | $128B | 97 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $726.94 | -1.12% | $74.9B | 94 5-pillar |
| BMY Bristol-Myers Squibb Company | $58.81 | -3.83% | $125B | 92 5-pillar |
| AMGN Amgen Inc. | $402.98 | -0.01% | $217B | 84 5-pillar |
| GILD Gilead Sciences, Inc. | $144.63 | -0.08% | $179B | 65 5-pillar |
| ICCC ImmuCell Corporation | $9.75 | 0.00% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $16.90 | -1.05% | $90.6M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.55 | +1.34% | $186M | 76 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INFIQ's Key Strengths?
Innovative product pipeline with a focus on immuno-oncology.
- Established strategic alliances with leading pharmaceutical companies.
- Experienced management team with expertise in drug development.
What Are INFIQ's Weaknesses?
Current financial instability due to Chapter 11 liquidation.
- Limited revenue generation with no current products on the market.
- High operational risk associated with clinical trial outcomes.
What Are the Key Risks for INFIQ?
The ongoing financial instability due to Chapter 11 liquidation may hinder operational effectiveness.
- High operational risk associated with the success of clinical trials, which are critical for future product viability.
- Intense competition in the oncology market could limit market share and profitability.
What Threats Does INFIQ Face?
- Intense competition in the biotechnology and oncology sectors.
- Regulatory hurdles that could delay product approvals.
- Market volatility impacting investor confidence and funding.
What Are INFIQ's Competitive Advantages?
- Strong focus on immuno-oncology, a rapidly growing field in cancer treatment.
- Strategic partnerships with established pharmaceutical companies enhance credibility and resources.
- Innovative product candidates with unique mechanisms of action set the company apart from competitors.
- Experienced leadership team with a track record in drug development and commercialization.
What Does INFIQ Do?
Founded in 1995 and headquartered in Cambridge, Massachusetts, Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative medicines for cancer treatment. The company has carved a niche in the biotechnology sector with its focus on immuno-oncology, particularly through its lead product candidate, eganelisib (IPI-549). This orally administered drug is currently in Phase 2 clinical trials targeting metastatic triple negative breast cancer and urothelial cancer, as well as in Phase 1/1b trials for solid tumors. Infinity has established strategic alliances with several companies, including Intellikine, Inc. for the development of PI3K-targeted therapies, Verastem, Inc. for the commercialization of duvelisib, and PellePharm, Inc. for its hedgehog inhibitor program, IPI-926. These collaborations enhance Infinity's research capabilities and market reach. However, the company faced significant financial challenges, culminating in a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on September 29, 2023. The reorganization plan was later approved as a Chapter 11 liquidation on March 7, 2024, impacting its operations and future prospects.
What Products and Services Does INFIQ Offer?
- Develop novel medicines specifically targeting cancer treatment.
- Focus on immuno-oncology therapies to enhance patient outcomes.
- Conduct clinical trials for lead product candidates, including eganelisib.
- Establish strategic alliances with other biopharmaceutical companies to expand research capabilities.
- Engage in the commercialization of innovative cancer therapies.
- Navigate regulatory processes for drug approval and market entry.
How Does INFIQ Make Money?
- Generate revenue through partnerships and collaborations in drug development.
- Focus on clinical trial successes to drive future product sales.
- Leverage strategic alliances to share development costs and risks.
- Seek licensing agreements for drug commercialization in various markets.
- Utilize research grants and funding for ongoing clinical projects.
What Industry Does INFIQ Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in oncology. The global cancer therapeutics market is projected to grow substantially, driven by increasing cancer incidence and advancements in personalized medicine. Companies like Infinity Pharmaceuticals, which are focused on immuno-oncology, are positioned to benefit from these trends. However, the competitive landscape is intense, with numerous players vying for market share in developing effective cancer treatments, highlighting the importance of successful clinical trial outcomes and strategic partnerships.
Who Are INFIQ's Key Customers?
- Healthcare providers and hospitals seeking innovative cancer treatments.
- Pharmaceutical companies interested in collaboration for drug development.
- Investors looking for opportunities in the biotechnology sector.
- Patients requiring advanced cancer therapies.
- Regulatory bodies for drug approval and compliance.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Earnings Track Record
Infinity Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 2 of its last 4 reported quarters — more hits than misses. Reported results have landed about 79.7% below estimates on average.
Company Profile
Infinity Pharmaceuticals, Inc. operates in the Healthcare sector. It is headquartered in Cambridge, US. INFIQ has traded publicly since 2000.
Forward Outlook
Wall Street analysts project Infinity Pharmaceuticals, Inc. revenue of about $18.0M for fiscal 2026, with EPS near $-0.13.
INFIQ Financials
INFIQ Latest News
No recent news available for INFIQ.
INFIQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for INFIQ.
Price Targets
Wall Street price target analysis for INFIQ.
INFIQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for INFIQ; grades run from A+ (80-100) to F (below 30).
Leadership: Lawrence E. Bloch
CEO
Lawrence E. Bloch has extensive experience in the biopharmaceutical industry, having held various leadership roles throughout his career. He has a strong background in drug development and commercialization, with a focus on oncology. His educational credentials and experience in managing clinical-stage companies position him well to lead Infinity Pharmaceuticals through its current challenges.
Track Record: Under Lawrence's leadership, Infinity has pursued strategic collaborations with major pharmaceutical companies, enhancing its research capabilities and market reach. His focus on innovative cancer therapies has guided the company's product development efforts.
INFIQ OTC Market Information
The OTC Other tier includes companies that do not meet the listing requirements for the major exchanges like NYSE or NASDAQ. These companies often have lower visibility and liquidity, making them riskier investments. However, they can provide opportunities for investors willing to take on additional risk.
- OTC Tier: OTC Other
- High volatility associated with OTC stocks, particularly in the biotechnology sector.
- Limited financial transparency due to bankruptcy proceedings.
- Potential for significant losses if clinical trials do not yield positive results.
- Verify the status of ongoing clinical trials and their outcomes.
- Assess the financial health and restructuring plans post-bankruptcy.
- Review partnerships and collaborations for potential revenue streams.
- Monitor industry trends in oncology and immuno-oncology.
- Evaluate the management team's experience and track record.
- Established partnerships with reputable pharmaceutical companies.
- Presence in clinical trials, indicating ongoing research and development.
- Historical focus on innovative cancer therapies, aligning with market needs.
What Investors Ask About Infinity Pharmaceuticals, Inc. (INFIQ) — Healthcare
How does Infinity Pharmaceuticals, Inc. manage patent expiration risks?
Infinity Pharmaceuticals, Inc. has strategies in place to manage patent expiration risks, including ongoing research and development of new compounds that could replace or supplement existing products.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The company is currently undergoing Chapter 11 liquidation, which significantly impacts its operational status and financial reporting.